<DOC>
	<DOCNO>NCT01012258</DOCNO>
	<brief_summary>Primary objective : assess antitumor activity safety profile cetuximab give combination radiotherapy ( RT ) treatment locally advance squamous cell carcinoma head neck ( SCCHN ) Chinese subject . Secondary objective : assess pharmacokinetic ( PK ) profile immunogenicity cetuximab Chinese subject . Further objective : identify cetuximab potential predictive biomarkers response safety .</brief_summary>
	<brief_title>Cetuximab With Radiotherapy Locally Advanced Squamous Cell Carcinoma Head Neck Chinese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inpatient great equal ( &gt; = ) 18 year age Pathologically proven squamous cell carcinoma arise oropharynx , hypopharynx larynx Stage III IV disease expect survival least 12 month Medically suitable withstand course concomitant boost RT Presence least 1 bidimensionally measurable lesion identify either compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) accord modify World Health Organization ( WHO ) criteria Karnofsky Performance Status ( KPS ) &gt; =80 trial entry Neutrophils &gt; =1.5*10^9/Liter ( L ) , platelet count &gt; = 100*10^9/L , hemoglobin &gt; = 90 gram/liter ( g/L ) Total bilirubin less equal ( &lt; = ) 2*upper limit normal ( ULN ) ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; = 3*ULN Serum creatinine &lt; =133 micromole/liter ( mcmol/L ) Serum calcium within normal range Effective contraception procreative potential exists ( applicable male female subject ) Chinese Chinese citizenship Signed write informed consent Evidence distant metastatic disease Squamous cell carcinoma arise nasopharynx oral cavity Receipt prior systemic chemotherapy within last 3 year Previous surgery tumor study biopsy Receipt prior RT head neck Currently receive RT part postoperative regimen follow primary surgical resection Planned neck dissection trial RT Active infection ( infection require IV antibiotic ) , include active tuberculosis , know declared human immunodeficiency virus ( HIV ) Uncontrolled diabetes mellitus , pulmonary fibrosis , acute pulmonary disorder , interstitial pneumonia , cardiac failure liver failure Uncontrolled hypertension define systolic blood pressure &gt; =180 millimeter mercury ( mmHg ) and/or diastolic blood pressure &gt; =130 mmHg rest condition Pregnancy ( absence confirm serum beta human chorionic gonadotrophin [ betaHCG ] test ) breastfeeding Concomitant chronic systemic immune therapy hormonal therapy cancer therapy Other concomitant anticancer therapy Documented symptomatic brain leptomeningeal metastasis Clinically relevant coronary artery disease history myocardial infarction last 12 month high risk uncontrolled arrhythmia uncontrolled cardiac insufficiency Previous treatment monoclonal antibody therapy , signal transduction inhibitor epidermal growth factor receptor ( EGFR ) target therapy Evidence previous malignancy within last 5 year Intake investigational medication within 30 day trial entry Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>antitumor activity</keyword>
	<keyword>safety</keyword>
	<keyword>cetuximab combination radiotherapy</keyword>
	<keyword>locally advanced squamous cell head &amp; neck carcinoma</keyword>
</DOC>